関連する実験動画

Updated: May 10, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

アルデヒド改変型アポリポプロテインB-100ペプチド配列に対する再結合ヒト抗体は,動脈硬化症を抑制する

Alexandru Schiopu¹, Jenny Bengtsson, Ingrid Söderberg

¹Department of Medicine, Malmö University Hospital, Lund University, Malmö, Sweden. Alexandru.Schiopu@medforsk.mas.lu.se.

|September 29, 2004

まとめ

酸化LDLを標的とする抗体,特にマロンディアルデヒド改変型アポリポプロテインB-100ペプチドは,マウスの動脈硬化症を減少させた. これは,被動免疫が心血管疾患の新しい治療法を提供することを示唆しています.

科学分野:

免疫学免疫学とは
心血管研究循環器科の研究
動脈硬化症 (Atherosclerosis) とは,動脈硬化症 (Atherosclerosis) とは,動脈硬化症 (Atherosclerosis) とは,動脈硬化症のことです.

背景:

低密度脂質タンパク質 (LDL) の蓄積と酸化は,動脈硬化症の発症の鍵です.
酸化されたLDL,特にアルデヒド改変型アポリポプロテインB-100 (apoB-100) ペプチドに対する免疫反応は,保護的かもしれない.
酸化されたLDLは免疫系によって認識されます.

研究の目的:

酸化LDLに対する抗体の治療的可能性を調査する.
動脈硬化症における免疫反応の役割を調査する.
心血管疾患の新たな治療法を開発する.

主な方法:

マロンディアルデヒド (MDA) 改変アポB-100ペプチドに対するヒトIgG1抗体を生成した.
apoE-/-マウスに対する抗体投与と動脈硬化症の評価.
モノサイト結合と酸化LDLの吸収に対する抗体の評価効果 in vitro.

主要な成果:

1つの抗体は,大動脈硬化症の範囲と酸化されたLDLとマクロファージのプラーク含有量を,投与量に依存した方法で有意に減少させた.
抗体は単細胞結合と細胞培養における酸化LDLの吸収を増加させた.
対照抗体はこれらの効果を示さなかった.

結論:

MDA改変のapoB-100ペプチドを標的にする抗体は,アテロ保護性免疫応答を媒介する.
これらのエピトープに対する被動免疫は,心血管疾患の潜在的な治療戦略を表しています.
動脈硬化症に対する抗体ベースの治療法に関するさらなる研究が必要である.

さらに関連する動画

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

関連する概念動画

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...